Human P16 Antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
p16 (cyclin-dependent kinase inhibitor 2A, INK4a) is a tumor suppressor protein. It is a specific inhibitor of Cdk 4/Cdk 6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16 INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16 INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16 INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia.
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Human P16 |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | ELISA: 1/10000, IHC: 1/200 - 1/1000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG1 |
| Purification | Unpurified ascites. |
| Size 1 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA, IHC |
| Buffer | Ascitic fluid containing 0.03% sodium azide. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P42771 |
| Gene ID | 1029 |
| OMIM | 155601 |
| Background | Antibody anti-P16 |
| Status | RUO |
| Note | Concentration: Not determined. - |
Descripción
Related Products
Human P16 Antibody
p16 (cyclin-dependent kinase inhibitor 2A, INK4a) is a tumor suppressor protein. It is a specific inhibitor of Cdk 4/Cdk 6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16 INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16 INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16 INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia.
Ver Producto
P16 (Mouse and Human) Antibody
The progression of cells through the cell cycle is regulated by a family of protein kinases known as cyclin-dependent kinases (Cdks).The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle.The cyclins function as differentially expressed positive regulators of Cdks.Negative regulators of the cycle include the p53-inducible 21 kDa WAF1/Cip1 protein designated p21, Kip1 p27 and p16.The complexes formed by Cdk4 and the D-type cyclins have been strongly implicated in the control of cell proliferation during the G1 phase.It has recently been shown that p16 binds to Cdk4 and inhibits the catalytic activity of the Cdk4/cyclin D complex.Moreover, the gene encoding p16 exhibits a high frequency of homozygous deletions and point mutations in established human tumor cell lines.
Ver Producto
P16 (Mouse and Human) Antibody
The progression of cells through the cell cycle is regulated by a family of protein kinases known as cyclin-dependent kinases (Cdks).The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle.The cyclins function as differentially expressed positive regulators of Cdks.Negative regulators of the cycle include the p53-inducible 21 kDa WAF1/Cip1 protein designated p21, Kip1 p27 and p16.The complexes formed by Cdk4 and the D-type cyclins have been strongly implicated in the control of cell proliferation during the G1 phase.It has recently been shown that p16 binds to Cdk4 and inhibits the catalytic activity of the Cdk4/cyclin D complex.Moreover, the gene encoding p16 exhibits a high frequency of homozygous deletions and point mutations in established human tumor cell lines.
Ver Producto